What Happens to Your Sleep When You Take Magnesium and Melatonin Together

In 2019, researchers in Belgrade handed 60 people with moderate insomnia a nightly pill containing magnesium, melatonin, and a B-vitamin complex. They kept it up for three months. The treatment group’s Athens Insomnia Scale scores dropped from 14.93 — moderate clinical insomnia — to 10.50, edging into the mild range. The placebo group got worse: 14.37 to 15.13.

Across every subscale the combination pill beat placebo. Sleep induction. Night awakenings. Total sleep duration. Daytime functioning. p = 0.000. And yet — the study, published in the Open Access Macedonian Journal of Medical Sciences, has been cited fewer than 20 times in six years. It exists in a research landscape that sleep medicine specialists describe as “substandard for physicians to make well-informed recommendations.”

That’s the whole story, really. A genuine signal sitting inside a thin evidence base. Biologically, the mechanisms make sense. The trial data points to small, conditional benefits. And the people most likely to feel a difference are the ones who are running low on magnesium in the first place.

Why the combination makes mechanical sense

Magnesium and melatonin reach sleep through separate routes, and the reason researchers keep pairing them is that the pathways barely intersect.

Magnesium is a cofactor for the enzyme that converts 5-HTP into serotonin — and serotonin is the direct precursor for melatonin synthesis. It also binds to GABA-A receptors, the same receptor family that benzodiazepines and z-drugs like zolpidem target, which quiets neuronal excitability and nudges the body toward the parasympathetic “rest and digest” state. On top of that, it suppresses the hypothalamic-pituitary-adrenal axis, dragging down evening cortisol levels, which tend to run high in people with insomnia.

Melatonin doesn’t sedate. What it does is signal the suprachiasmatic nucleus — the brain’s master clock — that darkness has arrived, pushing the body into circadian night mode. Oral melatonin mostly amplifies a signal your pineal gland is already supposed to be sending.

RDN Olayide Adejumobi, M.S., put it cleanly in a 2025 EatingWell piece: “Magnesium and melatonin may support sleep in different but complementary ways. Melatonin helps with the timing of sleep, while magnesium may help the body feel more relaxed.”

The word to hold onto there is may. The mechanistic scaffolding is sound, but mechanism and clinically meaningful outcomes are different animals — and the trial data is where things get messier.

What the magnesium trials actually show

The cleanest data on magnesium alone comes from a 2025 RCT by Julius Schuster and colleagues at Leibniz University Hannover, published in Nature and Science of Sleep. They gave 155 healthy adults with self-reported poor sleep either 252 mg of elemental magnesium as bisglycinate or a placebo. Four weeks.

Insomnia Severity Index scores fell by 3.9 points in the magnesium group. Placebo group: 2.3 points. The gap was statistically significant — p = 0.049 — but Cohen’s d was 0.2. Small. You’d need to treat about 14 people with magnesium before one person notices a meaningful improvement beyond what a sugar pill would do.

A 2021 systematic review and meta-analysis by Mah and Pitre, published in BMC Complementary Medicine and Therapies, pooled three RCTs covering 151 older adults. Magnesium cut sleep onset latency by 17.36 minutes versus placebo. p = 0.0006. Real finding. Then the authors graded their own evidence: low to very low. All three trials carried moderate-to-high risk of bias. Their conclusion didn’t pull punches: “This review confirms that the quality of literature is substandard for physicians to make well-informed recommendations on usage of oral magnesium for older adults with insomnia.”

Seventeen minutes is not nothing. But the studies that produced that number aren’t the kind you build a clinical guideline on.

And what the combination trials add

The Djokic 2019 trial is the flashiest result — and the hardest to interpret. It used a triple-ingredient formulation: magnesium, melatonin, and B-complex vitamins. You can’t tell which component moved the needle. The B vitamins weren’t just window dressing either; B6 is a cofactor in the serotonin-to-melatonin conversion pathway.

A 2021 four-arm trial by Alizadeh and colleagues worked with women who had polycystic ovary syndrome, comparing magnesium alone, melatonin alone, both, and placebo. The combination won — largest PSQI improvement. But the magnesium was oxide, which has an absorption rate of about 4%. That makes the positive signal harder to wave off as placebo noise, but also harder to generalise. PCOS brings metabolic and hormonal disruptions that a metabolically healthy adult simply doesn’t share.

Then there’s Cruz-Sanabria’s 2024 paper, published in Chronobiology International, which tested a fixed-dose combination — 1.9 mg melatonin, 200 mg magnesium — in a novel delivery system. Twenty-six RCTs, 1,689 participants. Sleep efficiency, latency, and total sleep time all improved. But mean PSQI scores in the treatment group still sat above 5, the clinical cutoff for poor sleep. The combination helped. It didn’t turn poor sleepers into good ones.

The deficiency wildcard

Here’s the variable almost none of these trials controlled for: how much magnesium did the participants already have?

Roughly 53% of US adults fall short of the Estimated Average Requirement for dietary magnesium, per NHANES 2013–2016 data. The EAR is the intake level where half the population’s physiological needs are met — dip below it and your body is operating on thinner margins, even if you’re not clinically deficient.

Sweat burns off magnesium. Alcohol depletes it. Gut inflammation or disproportionately high calcium intake cuts absorption further. Someone eating a magnesium-light diet who runs four times a week and unwinds with a glass of wine could easily be in a chronic deficit without knowing it.

This is where the clinical data and the anecdotal reports converge, and it’s probably the most important lens for reading the evidence. The Schuster 2025 trial didn’t screen for deficiency — it enrolled healthy adults, period — and still found a statistically significant effect. Recruit only people with low magnesium status and that Cohen’s d of 0.2 would almost certainly climb. Board-certified behavioral sleep medicine psychologist Shelby Harris has pointed out that the people most likely to notice a difference from magnesium glycinate are the ones starting from a shortfall.

Which form of magnesium are we even talking about?

Not all magnesium is the same thing in a different bottle. Bioavailability spans a factor of about 20 between the best and worst forms, and the form used in a trial determines how much magnesium actually reaches your bloodstream.

Magnesium glycinate — or bisglycinate — is the form Schuster 2025 used. It’s magnesium bound to glycine, an amino acid that has its own inhibitory activity at NMDA receptors and may independently nudge the brain toward sleep. Absorption runs around 80%, and it’s the form least likely to cause gastrointestinal trouble. This is the one with actual clinical trial data behind it for sleep.

Magnesium threonate was developed at MIT. It crosses the blood-brain barrier more efficiently than other forms, and the cognitive research is underway. But there are zero published sleep-specific RCTs for it.

Magnesium citrate is more bioavailable than oxide — roughly 25% — but it’s mostly used as an osmotic laxative. At doses that might help sleep, GI side effects are common enough to limit adherence.

Magnesium oxide sits at about 4% bioavailability. It’s what Alizadeh 2021 used — which makes the positive result interesting, but also means that study says almost nothing about what glycinate or threonate would do at equivalent doses.

If you’re going to try magnesium for sleep, glycinate has the strongest evidence. But a trap worth flagging: the Schuster 2025 dose was 252 mg of elemental magnesium, not 252 mg of magnesium glycinate. Magnesium glycinate is only about 14% elemental magnesium by weight. Check the label — a lot of products advertise the compound weight and bury the elemental number. And consult your doctor before starting any supplement.

What the AASM says — and why it matters

The American Academy of Sleep Medicine’s 2017 Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia came down with a weak recommendation against melatonin for chronic insomnia in adults. The committee reviewed 14 studies. Melatonin reduced sleep onset latency by a weighted mean of about 7 minutes. They judged that clinically marginal.

There’s an obvious tension between the AASM’s stance and the supplement industry’s framing of melatonin as a go-to sleep aid. Part of the gap is the population: the guideline addresses adults with diagnosed chronic insomnia disorder, which isn’t the same group as the much larger pool of people who sleep poorly a few nights a week. But the distance between “this helps with jet lag” and “take this every night for insomnia” is real, and the AASM’s rating reflects the evidence on the books, not the marketing.

Magnesium doesn’t have an AASM guideline at all. It’s a dietary mineral, not a drug, so it sits outside the scope of pharmacologic treatment reviews. Consumers are left navigating a category where the claims run well ahead of the data.

So what actually happens when you take them together?

If your magnesium status is fine and your circadian rhythm is functioning — honestly, probably not much. The effect sizes are small. The evidence quality is low.

If you’re magnesium-deficient, which describes roughly half of US adults by dietary intake, the picture shifts. Sleep onset latency might drop by 10 to 20 minutes. Nighttime awakenings might ease a bit. You might wake up feeling like the sleep was deeper, even if the objective numbers are modest. The Djokic 2019 data hints that the combination outperforms either supplement alone — but that’s one study, a triple-ingredient pill, and 60 people.

The doses that show up in the trials: 200 to 250 mg of elemental magnesium as glycinate or bisglycinate, and 1 to 4 mg of melatonin, taken 30 to 60 minutes before bed. Cruz-Sanabria’s 2024 dose-response analysis pegged 4 mg as the sweet spot for melatonin in reducing sleep onset latency — but most over-the-counter melatonin products pack 3 to 10 mg, often well past what the data supports.

A few cautions. Magnesium at therapeutic doses can cause loose stools. It interacts with some antibiotics and bisphosphonates. Anyone with impaired kidney function should avoid it or take it under supervision. Melatonin can interact with blood thinners, immunosuppressants, and diabetes medications. And the person-to-person variation is wide — 0.5 mg knocks some people out, while others take 10 mg and feel nothing.

The fairest summary: magnesium and melatonin are not a cure for bad sleep. They are a reasonable, low-cost thing to try — with a doctor’s sign-off — if your sleep hygiene is already solid and you have reason to think your magnesium intake is low. Don’t expect a drug-strength effect. The data doesn’t support one.

References

1. Schuster J, et al. Magnesium bisglycinate supplementation in healthy adults reporting poor sleep: a randomized, double-blind, placebo-controlled trial. Nature and Science of Sleep. 2025. https://dovepress.com/magnesium-bisglycinate-supplementation-in-healthy-adults-reporting--peer-reviewed-fulltext-article-NSS
2. Mah J, Pitre T. Oral magnesium supplementation for insomnia in older adults: a systematic review and meta-analysis. BMC Complementary Medicine and Therapies. 2021. https://pubmed.ncbi.nlm.nih.gov/33865376/
3. Cruz-Sanabria F, et al. The effects of melatonin and magnesium in a novel supplement delivery system on sleep scores. Chronobiology International. 2024. https://pubmed.ncbi.nlm.nih.gov/38745424/
4. Djokic G, et al. The effects of magnesium-melatonin-vit B complex supplementation in treatment of insomnia. Open Access Macedonian Journal of Medical Sciences. 2019. https://pmc.ncbi.nlm.nih.gov/articles/PMC6910806/
5. Sateia MJ, et al. Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults. Journal of Clinical Sleep Medicine. 2017. https://jcsm.aasm.org/doi/10.5664/jcsm.6470
6. Alizadeh M, et al. Effect of magnesium and melatonin supplementation on sleep quality in women with PCOS. Nutrition & Metabolism. 2021. https://link.springer.com/article/10.1186/s12986-021-00586-9